Claims
- 1. A compound of Formula I:
- 2. The compound of claim 1 in which R1 represents hydrogen and R2 represents hydrogen, hetero(C5)aryl or (C1-4)alkyl-substituted hetero(C5)aryl or together with the carbon atom to which both R1 and R2 are attached form (C3-5)cycloalkylene or (C5-6)heterocycloalkylene; X1 and X2 are both methylene and R3 represents (C2-6)alkenyl, (C6-12)aryl or hetero(C5-12)aryl, each optionally substituted by 1 to 5 radicals selected from a group consisting of (C1-4)alkyl, cyano, halo, halo-substituted (C1-4)alkyl, nitro, —X3NR9R9, —X3OR9, —X3SR9, —X3C(O)NR9R9, —X3C(O)OR9, —X3S(O)R10, —X3S(O)2R10 and X3C(O)R10, wherein X3 is a bond or (C1-2)alkylene, R9 at each occurrence independently is hydrogen, (C1-3)alkyl or halo-substituted (C1-3)alkyl and R10 is (C1-3)alkyl or halo-substituted (C1-3)alkyl; and R4 is —C(O)X4R11, wherein X4 is a bon, —O— or —NH— and R11 is (C1-6)alkyl, hetero(C5-12)cycloalkyl(C0-3)alkyl, (C6-10)aryl(C0-3)alkyl or hetero(C5-10)aryl(C0-3)alkyl, wherein any heterocycloalkyl, aryl or heteroaryl group comprising R1 optionally is substituted in the ring by —X5OR17, —X5NR17C(O)OR17, X5C(O)OR17 or —X5C(O)R18; and the N-Oxide derivatives, prodrug derivatives, protected derivatives, individual isomers and mixtures of isomers thereof; and the pharmaceutically acceptable salts and solvates of such compounds and N-oxide derivatives, prodrug derivatives, protected derivatives, individual isomers and mixtures of isomers thereof.
- 3. The compound of claim 2 in which R3 more preferably represents biphenyl, isooxazolyl, naphthyl, phenyl, pyridyl, thienyl or vinyl, each optionally substituted by 1 to 5 radicals selected from a group consisting of (C1-4)alkyl, cyano, hallo, halo-substituted (C1-4)alkyl, nitro, —X3NR9R9, —X3OR9, —X3SR9, —X3C(O)NR9R9, —X3C(O)OR9, —X3S(O)R10, —X3S(O)2R10 and —X3C(O)R10, wherein X3 is a bond or (C1-2)alkylene, R9 at each occurrence independently is hydrogen, (C1-3)alkyl or halo-substituted (C1-3)alkyl and R10 is (C1-3)alkyl or halo-substituted (C1-3)alkyl; and the N-oxide derivatives, prodrug derivatives, protected derivatives, individual isomers and mixtures of isomers thereof; and the pharmaceutically acceptable salts and solvates of such compounds and the N-oxide derivatives, prodrug derivatives, protected derivatives, individual isomers and mixtures of isomers thereof.
- 4. The compound of claim 3 in which R3 is biphenyl-2-yl, 2,4-bistrifluoromethylphenyl, 2,5-bistrifluoromethylphenyl, 4-tert-butylphenyl, 2bromophenyl, 3-bromophenyl, 4-bromophenyl, 2-bromo-5-fluorophenyl, 3-chloro-2-fluorophenyl, 2-chlorophenyl, 3-chlorophenyl, 4-chlorphenyl, 5-chlorothien-2-yl, 2-chloro-5-trifluoromethyl, 2-cyanophenyl, 3-cyanophenyl, 4-cyanophenyl, 1,5-dichlorophenyl, 2,6-dichlorophenyl, 3,4-dichlorophenyl, 2,3-difluorophenyl, 2,4-difluorophenyl, 3,4-difluorophenyl, 2-difluoromethoxyphenyl, 3-difluoromethoxyphenyl, 4-difluoromethoxyphenyl, 2,5-difluorophenyl, 2,6-difluorophenyl, 3.5-dimethylisooxaxol-4-yl, 3,5-dimethylphenyl, 2-fluoro-6-nitrophenyl, 2-fluorophenyl, 4-fluorophenyl, 2-fluoro-3-trifluoromethylphenyl, 2-fluoro-4-trifluoromethylphenyl, 2-fluoro-5-trifluoromethylphenyl, 2fluoro-6-trifluoromethylphenyl, 4-fluoro-2-trifluoromethylphenyl, 4-fluoro-3-trifluoromethylphenyl, 2-iodophenyl, 3-iodophenyl, 4-iodophenyl, 2-methoxyphenyl, 4-methoxyphenyl, 2-methylphenyl, 3-methylphenyl, 4-methylphenyl, 3-methyl-2-fluorophenyl, naphth-2-yl, 2-nitrophenyl, 3-nitrophenyl, 4-nitropheyl, 2,3,4,5,6-pentafluorophenyl, phenyl, prop-2-en-1-yl, pyrid-2-yl, pyrid-3-yl, pyrid-4-yl, 2-trifluoromethoxyphenyl, 3-trifluoromethoxyphenyl, 4-trifluoromethoxyphenyl, 3-trifluoromethylphenyl, 4-trifluoromethylphenyl, 2-trifluoromethylsulfanylphenyl, 3-trifluoromethylsulfanylphenyl, 4-trifluoromethylsulfanyl-phenyl, 2,3,4-trifluorophenyl, 2,3,5-trifluorophenyl, 2,4,6-trifluorophenyl, 2,4,5-trifluorophenyl or 2,3,6-trifluorophenyl; and R4 is 3-acetylbenzoyl, allyloxycarbonyl, 2-aminopyrid-3-ylcarbonyl, 6-aminopyrid-3-ylcarbonyl, benzo[1,3]dioxol-5-ylcarbonyl, benzoyl, 4-benzoylbenzoylcarbonyl, benzo[1,3]dioxol-5-ylcarbonyl, benofur-2-ylcarbonyl, biphenyl-4-ylcarbonyl, 4-bromobenzoyl, 3-bromothien-2-yl, tert-butoxycarbonyl, 3-tert-butoxycarbonyaminomethylbenzoyl, 4-tert-butoxycarbonylpiperazin-1-ylcarbonyl, 3-chlorobenzoyl, 4-chlorobenzoyl, 3-chlorothienylcarbonyl, cyclopentylcarbonyl, 3,4-difluorobenzoyl, 3,4-dimethoxybenzoyl, dimethylcarbamoyl, 4-ethoxycarbonylpiperazin-1-ylcarbonyl, 4-fluorobenzoyl, 3-fluoro-4-methoxybenzoyl, fur-2-ylcarbonyl, fur-3-ylcarbonyl, 4-fur-2-ylcarbonylpiperazin-1-ylcarbonyl, 3-hydroxybenzoyl, 4-hydroxybenzoyl, 4-hydroxypyrid-3-yl, 6-hydroxypyrid-3-yl, 1H-indol-4-ylcarbonyl, isopropylcarbamoyl, isobutyloxycarbonyl, isopropyloxycarbonyl, 3-methoxybenzoyl, 4-methoxybenzoyl, 3-methylbenzoyl, 5-methylthienylcarbonyl, 4-methylvaleryl, morpholin-4-ylcarbonyl, naphth-2-ylcarbonyl, naphth-2-ylsulfonyl, 3-phenozybenzoyl, 3-phenylacryloyl, phenylsulfonyl, pyrazin-2-ylcarbonyl, 3-ylacryl, pyrid-2-ylcarbonyl, pyrid-3-ylcarbonyl, pyrid-4-ylcarbonyl, quinol-2-ylcarbonyl, quinol-3-ylcarbonyl, thien-2-ylcarbonyl, thien-3-ylcarbonyl, thien-2-ylsulfonyl, 4-trifluoromethoxybenzoyl or 4-trifluoromethylbenzoyl, and the N-oxide derivatives, prodrug derivatives, protected derivatives, individual isomers and mixtures of isomers thereof; and the pharmaceutically acceptable salts and solvates of such compounds and the N-oxide derivatives, prodrug derivatives, protected derivatives, individual isomers and mixtures of isomers thereof.
- 5. The compound of claim 3 in which X1, X2 and R3 along with the sulfonyl moiety to which X1 and X2 are attached together represent a group having the following formula:
- 6. The compound of claim 5 in which n is 0, 1 or 2 and R22 at each occurrence independently is selected from a group consisting of (C1-4)alkyl, cyano, halo, halo-substituted (C1-4)alkyl, nitro, —OR9, —SR9 and —C(O)OR9, wherein R9 at each occurrence independently is hydrogen, (C1-3)alkyl or halo-substituted (C1-3)alkyl; and the N-oxide derivatives, prodrug derivatives, protected derivatives, individual isomers and mixtures of isomers thereof; and the pharmaceutically acceptable salts and solvates of such compounds and the N-oxide derivatives, prodrug derivatives, protected derivatives, individual isomers and mixtures of isomers thereof.
- 7. The compound of claim 6 in which R22 at each occurrence independently is selected from a group consisting of (C1-4)alkyl, bromo, carboxy, chloro, cyano, difluoromethoxy, fluoro, iodo, methoxy, nitro, trifluoromethoxy, trifluoromethyl and trifluorosulfanyl; and the N-oxide derivatives, prodrug derivatives, protected derivatives, individual isomers and mixtures of isomers thereof; and the pharmaceutically acceptable salts and solvates of such compounds and the N-oxide derivatives, prodrug derivatives, protected derivatives, individual isomers and mixtures of isomers thereof.
- 8. The compound of claim 7 in which at the first occurrence is attached at the ring carbon ortho or meta to the 1-position of the phenyl moiety; and the N-oxide derivatives, prodrug derivatives, protected derivatives, individual isomers and mixtures of isomers thereof; and the pharmaceutically acceptable salts and solvates of such compounds and the N-oxide derivatives, prodrug derivatives, protected derivatives, individual isomers and mixtures of isomers thereof.
- 9. The compound of claim 8 selected from a group consisting of:
N—{(R)-1-(Cyanomethyl-carbamoyl)-2-[2-(1,1-difluoro-methoxy)-phenylmethanesulfonyl]-ethyl}-nicotinamide; N—{(R)-1-(Cyanomethyl-carbamoyl)-2-[2-(1,1-difluoro-methoxy)-phenylmethanesulfonyl]-ethyl}-isonicotinamide, Pyridine-2-carboxylic acid-N—{(R)-1-(cyanomethyl-carbamoyl)-2-[2-(1,1-difluoro-methoxy)-phenylmethanesulfonyl]-ethyl}-amide; Pyrazine-2-carboxylic acid-N—{(R)-1-(cyanomethyl-carbamoyl)-2-[2-(1,1-difluoro-methoxy)-phenylmethanesulfonyl]-ethyl}-amide, N—{(R)-1-(Cyanomethyl-carbamoyl)-2-[2-(1,1-difluoro-methoxy)-phenylmethanesulfonyl]-ethyl}-6-hydroxy-nicotinamide; 2-Amino-N—{(R)-1-(cyanomethyl-carbamoyl)-2-[2-(1,1-difluoro-methoxy)-phenylmethanesulfonyl]-ethyl}-nicotinamide; 6-Amino-N—{(R)-1-(cyanomethyl-carbamoyl)-2-[2-(1,1-difluoro-methoxy)-phenylmethanesulfonyl]-ethyl}-nicotinamide; 3-Hydroxy-pyridine-2-carboxylic acid-N—{(R)-1-(cyanomethyl-carbamoyl)-2-[2-(1,1-difluoro-methoxy)-phenylmethanesulfonyl]-ethyl}-amide; Morpholine-4-carboxylic acid-{(R)-1-(4-cyano-tetrahydro-pyran-4-ylcarbamoyl)-2 [2-(1,1-difluoro-methoxy)-phenylmethanesulfonyl]-ethyl}-amide; Morpholine-4-carboxylic acid-{(R)-1-(4-cyano-1-methyl-piperidin-4-ylcarbamoyl)-2-[2-(1,1-difluoro-methoxy)-phenylmethanesulfonyl]-ethyl}-amide; (R)—N-Cyanomethyl-3-[2-(1,1-difluoro-methoxy)-phenylmethanesulfonyl]-2-(3,3-dimethyl-ureido)-propionamide; {(R)-1-(Cyanomethyl-carbamoyl)-2-[2-(1,1-difluoro-methoxy)-phenylmethanesulfonyl]-ethyl}-carbamic allyl ester; {(R)-1-(Cyanomethyl-carbamoyl)-2-[2-(1,1-difluoro-methoxy)-phenylmethanesulfonyl]-ethyl}-carbamic acid isopropyl ester; {(R)-1-(Cyanomethyl-carbamoyl)-2-[2-(1,1-difluoro-methoxy)-phenylmethanesulfonyl]-ethyl}-carbamic acid isobutyl ester; N—{(R)-1-(Cyanomethyl-carbamoyl)-2-[2-(1,1-difluoro-methoxy)-phenylmethanesulfonyl]-ethyl}-3,4-difluoro-benzamide; N—{(R)-1-(Cyanomethyl-carbamoyl)-2-[2-(1,1-difluoro-methoxy)-phenylmethanesulfonyl]-ethyl}-3-methyl-benzamide; Thiophene-2-carboxylic acid-{(R)-1-(Cyanomethyl-carbamoyl)-2-[2-(1,1-difluoro-methoxy)-phenylmethanesulfonyl]-ethyl}-amide; 4-Bromo-N—{(R)-1-(cyanomethyl-carbamoyl)-2-[2-(1,1-difluoro-methoxy)-phenylmethanesulfonyl]-ethyl}-benzamide, N—{(R)-1-(Cyanomethyl-carbamoyl)-2-[2-(1,1-difluoro-methoxy)-phenylmethanesulfonyl]-ethyl}-4-methoxy-benzamide; N—{(R)-1-(Cyanomethyl-carbamoyl)-2-[2-(1,1-difluoro-methoxy)-phenylmethanesulfonyl]-ethyl}-4-trifluoromethoxy-benzamide, Naphthalene-2-carboxylic acid-{(R)-1-(cyanomethyl-carbamoyl)-2-[2-(1,1-difluoro-methoxy)-phenylmethanesulfonyl]-ethyl}-amide; (E)-N—{(R)-1-(Cyanomethyl-carbamoyl)-2-[2-(1,1-difluoro-methoxy)-phenylmethanesulfonyl]-ethyl}-3-phenyl-acrylamide; 5-Methyl-thiophene-2-carboxylic acid-{(R)-1-(cyanomethyl-carbamoyl)-2-[2-(1,1-difluoro-methoxy)-phenylmethanesulfonyl]-ethyl}-amide; Biphenyl-4-carboxylic acid-{(R)-1-(cyanomethyl-carbamoyl)-2-[2-(1,1-difluoro-methoxy)-phenylmethanesulfonyl]-ethyl}-amide; 1H-Indole-5-carboxylic acid-{(R)-1-(cyanomethyl-carbamoyl)-2-[2-(1,1-difluoro-methoxy)-phenylmethanesulfonyl]-ethyl}-amide; Benzo[1,3]-dioxole-5-carboxylic acid-{(R)-1-(cyanomethyl-carbamoyl)-2-[2-(1,1-difluoro-methoxy)-phenylmethanesulfonyl]-ethyl}-amide Benzo[b]thiophene-2-carboxylic acid-{(R)-1-(cyanomethyl-carbamoyl)-2-[2-(1,1-difluoro-methoxy)-phenylmethanesulfonyl]-ethyl}-amide; N—{(R)-1-(Cyanomethyl-carbamoyl)-2-[2-(1,1-difluoro-methoxy)-phenylmethanesulfonyl]-ethyl}-3-phenoxy-benzamide; Quinoline-3-carboxylic acid-{(R)-1-(cyanomethyl-carbamoyl)-2-[2-(1,1-difluoro-methoxy)-phenylmethanesulfonyl]-ethyl}-amide; N—{(R)-1-(Cyanomethyl-carbamoyl)-2-[2-(1,1-difluoro-methoxy)-phenylmethanesulfonyl]-ethyl}-3-(1-phenyl-methanoyl)-benzamide; 4-Chloro-N—{(R)-1-(cyanomethyl-carbamoyl)-2-[2-(1,1-difluoro-methoxy)-phenylmethanesulfonyl]-ethyl}-benzamide; N—{(R)-1-(Cyanomethyl-carbamoyl)-2-[2-(1,1-difluoro-methoxy)-phenylmethanesulfonyl]-ethyl}-3-fluoro-4-methoxy-benzamide; 3Bromo-thiophene-2-carboxylic acid-N—{(R)-1-(Cyanomethyl-carbamoyl)-2-[2-(1,1-difluoro-methoxy)-phenylmethanesulfonyl]-ethyl}-amide; 3-Chloro-benzo[b]thiophene-2-carboxylic acid-{(R)-1-(cyanomethyl-carbamoyl)-2-[2-(1,1-difluoro-methoxy)-phenylmethanesulfonyl]-ethyl}-amide; 3-Chloro-thiophene-2-carboxylic acid-{(R)-1-(cyanomethyl-carbamoyl)-2-[2-(1,1-difluoro-methoxy)-phenylmethanesulfonyl]-ethyl}-amide; N—{(R)-1-(Cyanomethyl-carbamoyl)-[2-(1,1-difluoro-methoxy)-phenylmethanesulfonyl]-ethyl}-trifluoromethyl-benzamide; (R)—N-Cyanomethyl-3-[2-(1,1-difluoro-methoxy)-phenylmethanesulfonyl]-2-(naphthalene-2-sulfonylamino)-propionamide; Cyclopentanecarboxylic acid-{(R)-1-(cyanomethyl-carbamoyl)-2-[2-(1,1-difluoro-methoxy)-phenylmethanesulfonyl]-ethyl}-amide; N-[1R-cyanomethylcarbamoyl-2-(3-trifluoromethoxybenzylsulfonyl)ethyl]benzamide; N-[1R-cyanomethylcarbamoyl-2-(2-difluoromethoxybenzylsulfonyl)ethyl]benzamide; N-[1R-cyanomethylcarbamoyl-2-(2-trifluoromethoxybenzylsulfonyl)ethyl]benzamide; N-[1R-cyanomethylcarbamoyl-2-(3-difluoromethoxybenzylsulfonyl]benzamide; N-[1R-cyanomethylcarbamoyl-2 (2-difluoromethoxybenzylsulfonyl)ethyl]morpholine-4-carboxamide; N-[1R-(1-cyanocyclopropylcarbamoyl)-2-(2-difluoromethoxybenzylsulfonyl)ethyl]morpholine-4-carboxamide; and the N-oxide derivatives, prodrug derivatives, protected derivatives, individual isomers and mixtures of isomers thereof; and the pharmaceutically acceptable salts and solvates of such compounds and the N-oxide derivatives, prodrug derivatives, protected derivatives, individual isomers and mixtures of isomers thereof.
- 10. A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 1 in combination with a pharmaceutically acceptable excipient.
- 11. A method for treating a disease in an animal in which inhibition cathepsin S can prevent, inhibit or ameliorate the pathology and/or symptomatology of the disease, which method comprises administering to the animal a therapeutically effective amount of compound of claim 1 or a N-oxide derivative or individual isomer or mixture of isomers thereof; or a pharmaceutically acceptable salt or solvate of such compounds and the N-oxide derivatives, prodrug derivatives, protected derivatives, individual isomers and mixtures of isomers thereof.
- 12. A compound of Formula II:
- 13. The compound of claim 12 in which n is 1 to 2, R1 represents hydrogen and R2 represents hydrogen, hetero (C5)aryl or (C1-4)alkyl-substituted hetero (C5) or R1 and R2 together with the carbon atom to which both R1 and R2 are attached form (C3-5)cycloalkylene or (C5-6)heterocycloalkylene, R3 at the first occurrence is selected from a group consisting of difluoromethoxy, trifluoromethoxy, trifluorosulfanyl and nitro and R3 at the second occurrence, if present, is selected from a group consisting of (C1-4)alkyl, bromo, carboxy, chloro, cyano, difluoromethoxy, fluoro, iodo, methoxy, nitro, trifluoromethoxy, trifluoromethyl and trifluorosulfanyl and R4 is —C(O)X1R11 or —S(O)2X4R11, wherein X4 is a bond, —O— or —NR12—, wherein R12 is hydrogen or (C1-6)alkyl, and R11 is (C1-6)alkyl, (C1-12)cycloalkyl(C0-3)alkyl, hetero(C5-12)cycloalkyl(C0-3)alkyl, (C6-10)aryl(C0-3)alkyl, hetero(C5-10)aryl(C0-3)alkyl, hetero(C8-12)bicycloaryl(C0-3)alkyl, or phenyl(C0-3)alkyl, wherein the phenyl is substituted by —X5OR15 or —X5C(O)R15, wherein X5 is a bond or methylene and R15 is phenyl(C0-3)alkyl, wherein any aryl or heteroaryl group comprising R4 optionally is substituted in the ring by 1 to 2 substituents selected from (C1-6)alkyl, halo, halo-substituted (C1-3)alkyl, —X5NR17R17and —X5OR17, wherein X5 is a bond or (C1-6)alkylene, R17 is hydrogen, (C1-6)alkyl or halo-substituted (C1-3)alkyl; and the N-oxide derivatives, prodrug derivatives, protected derivatives, individual isomers and mixtures of isomers thereof; and the pharmaceutically acceptable salts and solvates of such compounds and the N-oxide derivatives, prodrug derivatives, protected derivatives, individual isomers and mixtures of isomers thereof.
- 14. The compound of claim 13 in which R22 at the first occurrence is nitro or difluoromethoxy in the ortho or meta position and R4 is allyloxycarbonyl, 2-aminopyridinylcarbonyl, benzo[1,3]dioxolylcarbonyl, benzothienzyl, benzoyl, 3-benzoylbenzoyl, 4-bromobenzoyl, 3-bromothienyl, biphenylylcarbonyl, 3-chlorobenzothienyl, 4-chlorobenzoyl, 3-chlorothienyl, cyclopentylcarbonyl, 3,4-difluorobenzoyl, dimethylcarbamoyl, 3,4-dimethoxybenzoyl, 4-fluorobenzoyl, 3-fluoro-4-hydroxybenzoyl, 2-hydroxypyridinylcarbonyl, 3-hydroxypyridinylcarbonyl, indolylcarbonyl, isobutyloxycarbonyl, isopropylcarbamoyl, isopropyloxycarbonyl, 4-methoxybenzoyl, methoxycarbonyl, 3-methylbenzoyl, 2-methylthienylcarbonyl, 4-methylvaleryl, morpholin-1-ylcarbonyl, naphthalenylcarbonyl, naphthalenylsulfonyl, phenoxycarbonyl, phenylacryloyl, phenylsulfonyl, pyrazinylcarbonyl, pyridinylcarbonyl, quinolyl, thienylcarbonyl, thienylsulfonyl, 4-trifluoromethoxybenzoyl or 4-trifluoromethylbenzoyl; and the N-oxides derivatives, prodrug derivatives, protected derivatives, individual isomers and mixtures of isomers thereof; and the pharmaceutically acceptable salts and solvates of such compounds and the N-oxide derivatives, prodrug derivatives, protected derivatives, individual isomers and mixtures of isomers thereof.
- 15. The compound of claim 14 in which R22 at the first occurrence is nitro or difluoromethoxy in the ortho position and R4 is benzoyl, indolyl. morpholin-4-ylcarbonyl, thienylcarbonyl or pyridinylcarbonyl optionally substituted in the ring by 1 to 2 substituents selected from fluoro and methyl; and the N-oxide derivatives, prodrug derivatives, protected derivatives, individual isomers and mixtures of isomers thereof; and the pharmaceutically acceptable salts and solvates of such compounds and the N-oxide derivatives, prodrug derivatives, protected derivatives, individual isomers and mixtures of isomers thereof.
- 16. The compound of claim 15 selected from a group consisting of:
N-[1R-cyanomethylcarbamoyl-2-(2-difluoromethoxybenzylsulfonyl)ethyl]-morpholine-4-carboximide;
thiophene-2-carboxylic acid-{(R)-1-(cyanomethyl-carbamoyl)-2-[2-(1,1-difluoro-methoxy)-phenylmethanesulfonyl]-ethyl}-amide; thiophene-3-carboxylic acid-{(R)-1-(cyanomethyl-carbamoyl)-2-[2-(1,1-difluoro-methoxy)-phenylmethanesulfonyl]-ethyl}-amide; N-{(R)-1-(cyanomethyl-carbamoyl)-2-[2-(1,1-difluoro-methoxy)-phenylmethanesulfonyl]-ethyl}-4-fluoro-benzamide;
morpholine-4-carboxylic acid-{(R)-1-(4-cyano1-methyl-piperidin-4-ylcarbamoyl)-2-[2-(1,1-difluoro-methoxy)-phenylmethanesulfonyl]-ethyl}-amide; 5-methyl-thiophene-2-carboxylic acid-{(R)-1-(cyanomethyl-carbamoyl)-2-[2-(1,1-difluoro-methoxy)-phenylmethanesulfonyl]-ethyl}-amide; 1H-indole-5-carboxylic acid-{(R)-1-(cyanomethyl-carbamoyl)-2-[2-(1,1-difluoro-methoxy)-phenylmethanesulfonyl]-ethyl}-amide; N-{(R)-1-(cyanomethyl-carbamoyl)-2-[2-(1,1-difluoro-methoxy)-phenylmethanesulfonyl]-ethyl}-3-methyl-benzamide, N-{(R)-1-(cyanomethyl-carbamoyl)-2-[2-(1,1-difluoro-methoxy)-phenylmethanesulfonyl]-ethyl}-3,4-difluoro-benzamide; N-{(R)-1-(cyanomethyl-carbamoyl)-2-[2-(1,1-difluoro-methoxy)-phenylmethanesulfonyl]-ethyl}-isonicotinamide; N-{(R)-1-(cyanomethyl-carbamoyl)-2-[2-(1,1-difluoro-methoxy)-phenylmethanesulfonyl]-ethyl}-morpholine-4-carboxamide; and the N-oxide derivatives, prodrug derivatives, protected derivatives, individual isomers and mixtures of isomers thereof; and the pharmaceutically acceptable salts and solvates of such compounds and the N-oxide derivatives, prodrug derivatives, protected derivatives, individual isomers and mixtures of isomers thereof.
- 17. A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 12 in combination with a pharmaceutically acceptable excipient.
- 18. A method for treating a disease in an animal in which inhibition of cathepsin S can prevent, inhibit or ameliorate the pathology and/or symptomatology of the disease, which method comprises administering to the animal a therapeutically effective amount of compound of claim 12 or a N-oxide derivative or individual isomer or mixture of isomers thereof, or a pharmaceutically acceptable salt or solvate of such of such compounds and N-oxide derivatives, prodrug derivatives, protected derivatives, individual isomers and mixtures of isomers thereof.
- 19. The use of a compound of Formula II:
- 20. A process for preparing a compound of Formula:
Parent Case Info
[0001] This Application claims the right of priority under U.S.C. § 119(e) of U.S. Provisional Applications Nos. 60/154,245, 60/171,831 and 60/224,552, filed Sep. 16, 1999, Dec. 22, 1999 and Aug. 10, 2000, respectively.
Provisional Applications (3)
|
Number |
Date |
Country |
|
60154245 |
Sep 1999 |
US |
|
60171831 |
Dec 1999 |
US |
|
60224552 |
Aug 2000 |
US |
Divisions (1)
|
Number |
Date |
Country |
Parent |
09663449 |
Sep 2000 |
US |
Child |
10256354 |
Sep 2002 |
US |